A glioma derived from astrocytes, with varying grades and prognosis.
Cerebral hemispheres
Astrocytoma
Origin: Glial cells
Grade: II-III
Severity: Moderate
Molecular Marker: IDH mutation
Age Range: 5-15 years
Life Expectancy: 5-10 years
Astrocytoma is a type of brain tumor that originates in the star-shaped brain cells known as astrocytes, which are part of the supportive tissue of the brain. These tumors can occur in various parts of the brain and spinal cord. The information provided indicates that the astrocytoma in question is located in the cerebral hemispheres.
The symptoms of astrocytoma vary depending on the location and size of the tumor. For tumors located in the cerebral hemispheres, common symptoms can include:
These symptoms occur due to the pressure the tumor exerts on surrounding brain tissues or as a result of the tumor disrupting normal brain function.
Surgery: The primary treatment for astrocytoma is the surgical removal of the tumor. The extent of removal depends on the tumor's location and how well-defined it is. Complete resection is often challenging, especially if the tumor is near critical brain regions.
Side effects*: Risks include infection, bleeding, and damage to surrounding brain tissue, which can lead to neurological deficits depending on the tumor's location.
Radiation Therapy: Often used after surgery to kill any remaining cancer cells and reduce the risk of recurrence. Techniques like stereotactic radiosurgery (SRS) may be employed for more precision.
Side effects: Side effects can include fatigue, hair loss, skin irritation at the treatment site, and potential cognitive changes over time.
Chemotherapy: Drugs such as temozolomide are commonly used, especially for high-grade astrocytomas. Chemotherapy may be administered in conjunction with radiation therapy.
Side effects: Common side effects are nausea, vomiting, loss of appetite, fatigue, and increased risk of infections due to lowered blood cell counts.
Targeted Therapy: Drugs that specifically target cancer cell pathways, such as bevacizumab, can be used, particularly for recurrent tumors.
Side effects: These can cause high blood pressure, bleeding, fatigue, and other organ-specific side effects depending on the target.
Immunotherapy: This approach aims to stimulate the body's immune system to fight the tumor cells. Various forms, including checkpoint inhibitors and vaccine therapies, are being tested in clinical trials.
Gene Therapy: Experimental techniques are being explored to modify the genes involved in cancer cell growth, with the potential to halt or reverse tumor progression.
Tumor Treating Fields (TTF): This is a novel treatment that uses electric fields to disrupt cancer cell division. TTF is being studied for its efficacy in combination with other treatments.
Clinical Trials: Ongoing trials are testing new drugs, combinations of existing treatments, and novel delivery methods, offering potential new avenues for treatment.
Side effects vary widely depending on the treatment and can include immune-related adverse events (immunotherapy) or unexpected reactions due to novel mechanisms (gene therapy and TTF).
The treatments mentioned are continually evolving. Surgical techniques and radiation therapies have been refined over the decades, with significant advancements in the 2000s and 2010s. Chemotherapy and targeted therapies have seen new drug approvals into the 2020s. Many experimental treatments are in various stages of clinical trials as of the early 2020s, reflecting ongoing research and potential future approvals.
Overall, the management of astrocytoma is a rapidly developing field, with continuous improvements in treatment outcomes due to advances in technology, pharmacology, and a deeper understanding of tumor biology.